A Prospective, Multicenter, Open-label, Phase IV Post-authorization Safety Study Conducted in India to Assess the Safety and Treatment Outcomes of Octocog Alfa in Real-world Practice for On-demand Treatment of Acute Bleeds in Previously Treated Severe Hemophilia A Patients in India
Latest Information Update: 22 Apr 2026
At a glance
- Drugs Octocog alfa (Primary)
- Indications Haemophilia A
- Focus Adverse reactions
- Sponsors Bayer
Most Recent Events
- 08 Apr 2026 Planned initiation date changed from 10 Mar 2026 to 29 May 2026.
- 17 Mar 2026 New trial record